ANZCTR search results

These search results are from the Australian New Zealand Clinical Trials Registry (ANZCTR).

You can narrow down the results using the filters

34128 results sorted by trial registration date.
  • safe@home: effectiveness and cost effectiveness of telemonitoring and virtual care supported by primary care for people living with chronic disease in low socioeconomic neighbourhoods on ambulance ramping, readmission and GP clinic bloc

    Our healthcare system urgently needs a major boost in efficiency to manage hospital bed shortages and lengthening waiting-lists for primary and secondary care consultations. Once a winter issue, the unrelenting pressure on our healthcare system by our ageing, multi-morbid population now persists across all seasons and is exacerbated by the recent pandemic and its aftermath. The safe@home project is a potential solution. Safe@home aims to reduce emergency department (ED) presentations (ambulance ramping), readmission and length of stay (hospital avoidance), out-of-hospital mortality and improve access to primary care (clinic block) and self-care. With a focus on chronic conditions with high healthcare utilisation (diabetes, COPD, and heart failure), Safe@home will use the Model for Large Scale Knowledge Translation combined with co-design methods and a prospective, non-blinded pragmatic randomised Usual Care led trial (RCT) and economic evaluation to test and implement a daily home telemonitoring model of care supported by health professionals, for people living with chronic disease in low socio-economic neighbourhoods. We will evaluate the intervention’s effectiveness and cost-effectiveness. It is the clinical decisions and actions taken based on information obtained by monitoring that will alter patient wellbeing and outcomes, rather than the monitoring itself.

  • NSW Government-Sponsored Clinical Trial: Extended supply of Oral Contraceptive Pills (OCPs) by Community Pharmacists

    The overall aim of this study is to evaluate the clinical and economic impact and implementation of a service model (intervention) delivered by community pharmacists in NSW and 5 pharmacies in ACT, e-supplying specific oral contraceptive pills for a specific patient cohort over a 12-month study period. Women must be aged between 18 to 35 years (inclusive), taking the pill for contraception purposes only, and has seen their GP/nurse practitioner for a review of their low-risk oral contraceptive pill in the last two years. Specific objectives are to: 1. Assess the accessibility and acceptability for patients managed and/or treated by community pharmacists. 2. Assess implementation uptake of the intervention including the reach, fidelity and adoption of the intervention in community pharmacies, participant characteristics, and variation in uptake by geographic region. 3. Assess the clinical and experience outcomes for patients managed and/or treated by community pharmacists. 4. Assess the safety of the intervention and identify any risks that need to be addressed for future implementation. 5. Qualitatively assess the acceptability and feasibility of the intervention to pharmacists, other care providers and participants using the service. 6. Identify contextual enablers and constraints to access, adoption, fidelity delivery, impact, sustainability, and generalisability of the intervention. 7. Conduct a health economic evaluation to determine the economic benefits from the intervention. The study will use a cohort study design to assess the clinical and economic and implementation of the intervention in NSW and ACT over a 12-month study period. The intervention is multicomponent including Pharmacist training and support and a Pharmacy consultation, using an IT program, applying a clinical management protocol. Pharmacies and pharmacists must meet the criteria of an 'approved pharmacy' and an 'approved pharmacist' outlined in the NSW Health Authority to participate. Primary outcomes will be accessibility and acceptability of the service (based on self-report at 7-day follow up).

  • Determining the optimal dose of omega-3 fatty acids in pregnancy for women with moderate status (OPAL-3 Study)

    This research project, called the OPAL-3 Study will help us determine the best dose of omega-3 supplements to give pregnant women, who have a moderate level of omega-3. Omega-3 fatty acids (DHA and EPA) are found in fish and fish oils and thought to have several health benefits including maintaining a pregnancy to full term (>37 weeks). Previous studies have shown that women who are low in omega-3 fatty acids are at increased risk of having a premature baby. This risk can be reduced by taking an omega-3 supplement containing DHA and EPA. Studies have also shown that women who have sufficient levels of omega-3 fatty acids have a lower risk of giving birth to a premature baby and do not need to take supplements. What is not clear from the research is the best advice to provide women with moderate omega-3 levels. The aim of this study is to work out the dose of omega-3 fatty acids (DHA and EPA) needed to best match the fatty acid levels of women who are sufficient in omega-3 fatty acids. This study will compare women who have moderate levels of omega-3 and taking different doses of study supplements to women who have sufficient levels of omega-3. We will also compare with women who have low levels of omega-3 and are taking the recommended dose to correct their low levels. This will be done by looking at the omega-3 levels in blood spot samples throughout pregnancy.

  • Point of care lactate testing for early paediatric sepsis recognition, antimicrobial administration, and management in the Emergency Department

    This research will examine the impact of implementing a point of care (PoC) lactate machine on the administration of antibiotics in paediatric patients presenting with potential sepsis in the Emergency Department (ED). Elevated lactate levels are proven to be an accurate prognostic factor in predicting morbidity among patients with sepsis. Current practice requires that serum lactate samples are collected via intravenous cannulation or venepuncture, a distressing procedure for children and parents and challenging and time-consuming for staff . The PoC lactate machine is a portable, single-operator handheld device requiring finger prick blood sampling to obtain accurate lactate results. This negates the need for intravenous cannulation or venepuncture to obtain objective data to aid clinical decision-making. This may result in the earlier recognition of sepsis, administration of antibiotics and transfer to definitive care.

  • A study to evaluate the Safety, Tolerability, Pharmacokinetics and Food-Effect of MRX-5 Tablets in Healthy Adult Subjects

    This double blind, placebo controlled, first-in-human study will assess the safety, tolerability of single and multiple oral doses of MRX-5 tablets in healthy men or women of non -child bearing potential and also to assess the pharmacokinetic (PK) profile of MRX-5 and its metabolite MRX-6038, and to compare the PK of a single dose of MRX-5 administered fed vs. fasted conditions. Who is it for? You may be eligible for this study if you are a healthy adult aged between 18 and 55 years old. Approximately 84 healthy participants will be enrolled in this study. (60 subjects in Part 1 and 24 subjects in Part 2) The total participation in the study will last around 5 weeks which consists of Screening visit, Admission and treatment period and Follow up visit.

  • What is the effect of wearing a surgical mask or an N95 mask on patients with stable chronic hypercapnic respiratory failure currently using non-invasive ventilation? A randomised cross-over trial

    This study will look at the effects of wearing surgical and N95 masks have in patients with respiratory failure currently using non-invasive ventilation. The aim of the study is to see whether this affects your oxygen or carbon dioxide levels as well as measures of comfort. The hypothesis of this study is there will not be a clinically important change in oxygen saturation and Transcutaneous carbon dioxide when wearing a surgical mask and N95 mask compared to no mask. There may be some changes in subjective comfort and breathlessness.

  • The response of the eye to different ocular allergy eyedrops

    The prevalence of ocular allergies is increasing worldwide, affecting individuals’ quality of life and causing a significant socioeconomic burden. Allergic conjunctivitis can be managed using a range of treatment options. Ocular inflammatory cell (e.g., dendritic cell) play a substantial role in initiating the immune response in the setting of ocular allergies. The proposed study will be single centre, double-blinded, randomised, placebo-controlled, parallel group clinical trial. All participants will go through a washout period for 1 week using topical 0.25% polyethylene glycol 400 eyedrops (lubricant eyedrops) before starting the trial interventions. This study consists of three arms; arm 1 will be given topical ketotifen 0.025% eyedrops; arm 2 will be given prednisolone sodium phosphate 0.5% eyedrops; the placebo group will be given topical 0.4% polyethylene glycol 400, 0.3% propylene glycol eyedrops. All participants will remain on the trial interventions for 14 days. Assessment of the trial outcomes will take place pre-treatment, 24 hours, 7 days and 14 days after starting the treatment, 7 days and 14 days post-treatment. Both investigators and participants will be double-blinded to the group and treatment allocation until the results have been analysed.

  • The feasibility and preliminary effectiveness of exercise therapy in transdiagnostic mental health services.

    Individuals living with a severe mental illness experience a significantly reduced life expectancy when compared to the general population, attributable in part to increased rates of cardiovascular diseases and metabolic syndromes that are associated with psychotropic medication use and poor health behaviours (e.g., low physical activity levels, poor diet quality and high sedentary time). There is a concerted effort to preserve (and improve) the physical health of individuals living with mental illness, with exercise increasingly advocated as part of mental health care due to the positive effect exercise has on physical and psychological health. One of the challenges for exercise services is to provide best practice exercise therapy, and support consumers to establish and maintain positive health behaviours in a client-centred and efficient manner. This trial will implement an effectiveness-implementation hybrid design to determine the feasibility and effectiveness of supported exercise therapy within transdiagnostic tertiary mental health care services. The aims are: • To determine the feasibility of implementation of low and high-support exercise therapy in a transdiagnostic tertiary mental health service. • To assess the preliminary effectiveness of low and high-support exercise therapy on consumer health outcomes including physical health outcomes, health behaviours, and quality of life.

  • A Phase 1 single and multiple ascending dose study of YA-101 in Healthy Subjects

    Multiple system atrophy (MSA) is a rare, severe and life-threatening adult-onset neurodegenerative disease, characterized by a combination of parkinsonism, cerebellar ataxia, and autonomic dysfunction. At present, only symptomatic therapy is available for the treatment of MSA, and most of the prescribed medications are being used in an off-label manner. YA-101 is being developed for the treatment of subjects with MSA, a serious and life-threatening condition with a high, unmet clinical need. The safety, tolerability, PK, and food effect of YA-101 will be evaluated in HV in Parts 1 and 2 of this study. The study will be conducted in healthy volunters aged between 18-65 years . Besides the one food effect (FE) cohort, each cohort in Part 1~Part 2 is randomized, placebo-controlled, double-blinded to establish safety and tolerability in healthy volunteers (HV) following single ascending dose (SAD) and multiple ascending dose (MAD). A total of 60 participants will be enrolled in Australia. Duration of the study Part 1 HV SAD: Total duration of study is up to 8 days with 1-day treatment Part 2 HV MAD: Total duration of study is up to 21 days, 14-day treatment Part 2 HV FE: Total duration of study is up to 11 days with 1-day treatment

  • Nutromics Biosensor Characterisation (NBC) Study to measure endogenous analytes in the interstitial space with a novel, minimally invasive biosensor in healthy participants.

    This is a characterisation research study investigating the different features of the Nutromics Sensor Device platform.Characterisation studies to help guide development of the Nutromics Sensor Device platform will provide invaluable information to Research and Development (R&D) teams. Since this is a minimally invasive patch based platform, with minimally invasive needle, characterisation of adhesive, ergonomics and human factors will be crucial.

Tags:
  • Finding clinical trials